Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia Reports Last Patient Study Visit in Aurora Phase 3 Lupus Nephritis Study and Provides Update on ATM Facility

Business Wire October 16, 2019

Aurinia Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

Business Wire September 26, 2019

Aurinia Establishes At-the-Market Facility

Business Wire September 13, 2019

Aurinia Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

Business Wire September 6, 2019

Aurinia Reports Second Quarter 2019 Financial Results and Operational Highlights

Business Wire August 6, 2019

Aurinia Pharmaceuticals to Release Second Quarter 2019 Financial Results on August 6, 2019

Business Wire August 1, 2019

Aurinia Announces Further Strengthening of the Senior Management Team

Business Wire July 18, 2019

ILJIN Comments on Aurinia Pharmaceutical's Annual Meeting

Business Wire June 27, 2019

Aurinia Shareholders Elect all Eight Directors at 2019 Annual General Meeting

Business Wire June 26, 2019

ILJIN Chairman Issues Open Letter to Aurinia Shareholders

Business Wire June 21, 2019

Aurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline

Business Wire June 21, 2019

As Deadline Approaches ILJIN SNT Reminds Aurinia Shareholders to Vote the GREEN Proxy for Nominees Committed to Correcting Governance Failures and to Realizing Aurinia's Full Potential

Business Wire June 20, 2019

Leading Independent Proxy Advisors Recommend Aurinia Shareholders Vote the YELLOW Proxy Card FOR All of Aurinia's Director Nominees

Business Wire June 19, 2019

ILJIN SNT Files Investor Presentation, Urging Aurinia Shareholders to Correct Governance Failures and Director Conflicts

Business Wire June 12, 2019

ILJIN SNT Sends Letter to Shareholders of Aurinia Highlighting Governance Failures and Director Conflicts and Responding to Misleading Information

Business Wire June 10, 2019

Aurinia Issues Letter to Shareholders

Business Wire June 7, 2019

Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire June 4, 2019

Largest Shareholder of Aurinia Pharmaceuticals, ILJIN SNT, Files Proxy Circular and Issues Letter to Fellow Shareholders

Business Wire June 3, 2019

Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting of Shareholders

Business Wire May 31, 2019

Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

Business Wire May 17, 2019